PBM-Owned Specialty Pharmacies Steer $300B in Prescriptions to Themselves

Each of the three major PBMs owns a specialty pharmacy — CVS Caremark owns CVS Specialty, Express Scripts owns Accredo, and OptumRx owns BriovaRx. These PBMs use their formulary design and network restriction power to force patients away from independent specialty pharmacies and toward their own vertically integrated pharmacies. A patient who has been successfully managed by a local specialty pharmacy for years can receive a letter saying their medication will only be covered if filled through the PBM's own mail-order specialty pharmacy. This matters because specialty drugs now represent over 50% of total U.S. drug spending despite being used by less than 2% of patients. When a PBM steers these high-cost prescriptions to its own pharmacy, it captures both the dispensing margin and the PBM administrative fee on the same transaction. The plan sponsor pays more because there is no competitive pressure on the PBM to negotiate lower prices with itself. A 2022 Drug Channels Institute analysis estimated that PBM-affiliated specialty pharmacies dispensed over 70% of specialty prescriptions. For patients, the pain is immediate and clinical. Specialty medications treat conditions like cancer, rheumatoid arthritis, multiple sclerosis, and hemophilia. These patients rely on specialized pharmacists who understand their disease, monitor side effects, and coordinate with their care team. When forced to switch to a PBM-owned mail-order pharmacy, patients lose that clinical relationship. Medications may arrive late, require complex cold-chain shipping that fails, or come without the patient education that a specialty pharmacist provides in person. Oncology patients have reported receiving chemotherapy drugs left on their doorstep in summer heat. The steering persists because PBMs control the formulary, the network, and the adjudication system simultaneously. They can designate a drug as "limited distribution" and restrict it to their own pharmacy without regulatory approval. The FTC's 2024 interim report on PBMs confirmed that vertical integration creates "significant incentives" for self-dealing. Yet no federal law prohibits a PBM from steering prescriptions to a pharmacy it owns. The root cause is that the same entity making coverage decisions also profits from dispensing. This is analogous to a judge owning the prison — the decision-maker has a financial interest in the outcome. Without mandatory firewalls between PBM benefit management and PBM-owned pharmacy operations, self-dealing is not a bug but the business model itself.